These findings collectively suggest that both genetic mutations and epigenetic modifications contribute to the altered expression and localization of Cx43 in NSCLC, potentially impacting tumor progression and patient outcomes. The gene discussed is GJA1; the disease is non-small cell lung carcinoma.